AMP Education Collaborations

Ovarian Cancer Virtual Education Series

In collaboration with expert clinicians, The European Society of Pathology (ESP), the Association for Molecular Pathology (AMP), AstraZeneca, & MSD have developed educational modules on diagnostic testing in ovarian cancer patients. This Virtual Education Series consists of key modules designed to provide training on the theoretical, technical, and practical aspects of diagnostic testing in ovarian cancer, as well as supporting videos and a self-assessment to ensure the principles and need for diagnostic testing are understood. 

This five-part series consists of key modules designed to provide training on the theoretical, technical, and practical aspects of diagnostic testing in ovarian cancer. 

KRAS Mutated NSCLC Resource Center: Updates on Diagnosis, New Therapies, and Management

New and emerging therapies have shown efficacy against the long elusive target of KRAS in NSCLC, creating a substantial new cohort of patients with targetable mutations. This PRIME resource center features interactive quizzes, expert-led discussions, and on-demand content designed to keep clinicians up-to-date on diagnostic strategies, emerging clinical efficacy and safety data, and overall management in an important new area of care for patients with lung cancer. Access Now

Applying Evidence-Based Treatment Strategies in NSCLC with KRAS Mutations

KRAS G12C-positive non-small cell lung cancer (NSCLC) is a sizable patient group with new and emerging targeted therapy options. Take part in this timely, interactive webinar from NSCLC experts to better understand how these therapies work and the clinical data guiding optimal use, as well as how to integrate the care of these patients into current evidence-based management of patients with NSCLC.

This activity is delivered in partnership with PRIME Education. Access Now

Advancing Patient Care in NSCLC: Breaking Down Barriers
This free online learning experience is aimed at breaking down barriers to testing and treatment in Non-Small Cell Lung Cancer (NSCLC).  Over the summer of 2018, world-renowned experts will explore the most best practices in test ordering, sample collection, and test interpretation with the goal of improving patient care. This five-part series is supported by an unrestricted educational grant provided by AstraZeneca.

Tumor Mutational Burden: Challenges and Opportunities for Improving Cancer Patient Care
This free online learning experience explores how measuring tumor mutational burden can improve patient care. This webinar series is supported by an unrestricted educational grant provided by Bristol-Myers Squibb.

Emerging Targets for the Diagnosis of Cancer: NTRK Fusion in Solid Tumors
Developed through a strategic collaboration between AMP and Medscape Education Oncology
Hosted live at the AMP 2018 Annual Meeting this educational event highlights best practices for testing for and reporting results of NTRK fusions as well as management of patients with TRK TKI therapy. A recorded version of this event can be accessed for free on the Medscape website using the link above.

Finding the Patient Perspective: Molecular Testing in Advanced NSCLC
Developed through a strategic collaboration between AMP and Medscape Education Oncology
Hosted live at the AMP 2018 Annual Meeting this educational event explores the patient perspective on molecular testing in NSCLC. A recorded version of this event can be accessed for free on the Medscape website using the link above.

Diagnostic Strategies in Advanced NSCLC: Guiding Treatment Decisions Through Pathology
Developed through a strategic collaboration between AMP and Medscape Education Oncology
Hosted live at the AMP 2017 Annual Meeting this educational event highlights clinical trial data and practice guidelines supporting the use of ALK, EGFR, ROS1, and PD-L1 status in the treatment selection for patients with advanced NSCLC. A recorded version of this event can be accessed for free on the Medscape website using the link above.

Association of Community Cancer Centers (ACCC) Virtual Molecular Tumor Boards (Through 2017)
As molecular testing becomes more widely adopted in the community oncology setting, cancer programs can benefit from access to innovative formats to help ensure that communication and quality patient care standards are maintained. Several innovative ACCC member programs have begun using virtual tumor board models as part of the integration of molecular testing into practice. The virtual format allows participation by a variety of providers across a wide geographic area. Members of multidisciplinary teams across sites are invited to join in the virtual discussion of cases and determine treatment - regardless of the physical location of the patient and care team. Building on interviews with select ACCC member programs, ACCC and our partner organization, the Association for Molecular Pathology (AMP), are developing a webinar series focused on virtual molecular tumor boards for lung and breast cancer. The 12-webinar series features case studies and robust discussions on molecular testing in the community setting.

"EGFR and NSCLC Diagnostic Strategies: What Should You Know?"
AMP has partnered with Medscape to develop this free online learning opportunity. This event was recorded live at the AMP 2016 Annual Meeting.  A recorded version of this event can be accessed on the Medscape website using the link above.

Molecular Oncology Tumor Boards
The Molecular Oncology Tumor Boards are a series of monthly user-driven discussions designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies. Moderated by an expert pathologist and medical oncologist, each case will be updated with new information over a two week period as user comments are added. After two weeks, the discussion forum will be locked to further commentary and users will be able to claim CME credit for their participation. This series is an educational collaboration between the American Society of Clinical Oncology (ASCO), the College of American Pathologists (CAP), and the Association for Molecular Pathology (AMP).